 SOUTH SAN FRANCISCO, Calif., May 24, 2021 GLOBE NEWSWIRE -- NGM Biopharmaceuticals, Inc. NGM Nasdaq: NGM, a biotechnology company focused on discovering and developing transformative therapeutics for patients, today reported results from the 24-week Phase 2b ALPINE 23 study evaluating aldafermin in 171 patients with biopsy-confirmed non-alcoholic steatohepatitis NASH with stage 2 or 3 liver fibrosis F2F3. The trial was an equally randomized, double-blind, placebo-controlled study that assessed the efficacy, safety and tolerability of 0.3 mg, 1 mg and 3 mg doses of aldafermin once-daily subcutaneous injections compared to placebo. The study did not meet its primary endpoint evaluating a dose response showing improvement in liver fibrosis by 1 stage with no worsening of NASH at week 24 p0.55, analyzed using a dose response-driven statistical analysis plan Multiple Comparison Procedure Modeling, or MCP-Mod. The study did achieve statistical significance versus placebo on certain secondary endpoints, including NASH resolution at the 3 mg dose and multiple non-invasive measures of NASH, including liver fat content reduction by MRI-PDFF, ALT, AST and Pro-C3 at the 1 mg and 3 mg doses. 